Overview Dividends

(DGX) Quest Diagnostics - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74834L1008

Clinical Testing, Pathology, Risk Assessment, Health IT

DGX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 10.41%
EPS Trend (3Y Correlation): 76.5%

DGX Revenue

Revenue Growth (3Y CAGR): 7.08%
Revenue Trend (3Y Correlation): 90.9%

Description: DGX Quest Diagnostics October 16, 2025

Quest Diagnostics Inc. (NYSE:DGX) is a U.S.-based provider of diagnostic testing and related information services, operating under the Quest Diagnostics brand and several subsidiaries (AmeriPath, Dermpath Diagnostics, ExamOne, Quanum). It offers a full spectrum of laboratory services-from routine blood work to advanced molecular and anatomic pathology-delivered through a nationwide network of labs, patient service centers, mobile phlebotomy, and digital platforms to physicians, hospitals, insurers, employers, and consumers.

Key metrics and industry drivers: • FY 2023 revenue reached approximately **$12.5 billion**, with a **~7 % operating margin**, reflecting steady demand for high-margin specialty testing. • The company’s growth is bolstered by the **aging U.S. population** and rising prevalence of chronic diseases, which increase utilization of lab services. • Medicare reimbursement reforms and the shift toward **outpatient and at-home testing** are accelerating demand for Quest’s mobile phlebotomy and digital health solutions, while also pressuring pricing dynamics.

For a deeper quantitative analysis, you may find ValueRay’s data platform useful for evaluating Quest Diagnostics’ valuation and risk profile.

DGX Stock Overview

Market Cap in USD	20,383m
Sub-Industry	Health Care Services
IPO / Inception	1996-12-17

DGX Stock Ratings

Growth Rating	67.3%
Fundamental	75.1%
Dividend Rating	60.8%
Return 12m vs S&P 500	-2.70%
Analyst Rating	3.89 of 5

DGX Dividends

Dividend Yield 12m	1.77%
Yield on Cost 5y	2.86%
Annual Growth 5y	7.58%
Payout Consistency	98.4%
Payout Ratio	26.3%

DGX Growth Ratios

Growth Correlation 3m	67.4%
Growth Correlation 12m	89.3%
Growth Correlation 5y	72.4%
CAGR 5y	9.97%
CAGR/Max DD 3y (Calmar Ratio)	0.45
CAGR/Mean DD 3y (Pain Ratio)	1.30
Sharpe Ratio 12m	0.74
Alpha	1.85
Beta	0.563
Volatility	20.08%
Current Volume	1434k
Average Volume 20d	1029.7k
Stop Loss	172.9 (-3%)
Signal	0.29

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (969.0m TTM) > 0 and > 6% of Revenue (6% = 651.0m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.52% (prev 5.57%; Δ -3.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.89b > Net Income 969.0m (YES >=105%, WARN >=100%)

Net Debt (5.95b) to EBITDA (2.14b) ratio: 2.78 <= 3.0 (WARN <= 3.5)

Current Ratio 1.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (113.0m) change vs 12m ago 0.0% (target <= -2.0% for YES)

Gross Margin 33.30% (prev 32.77%; Δ 0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 67.20% (prev 59.27%; Δ 7.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.60 (EBITDA TTM 2.14b / Interest Expense TTM 282.0m) >= 6 (WARN >= 3)

Altman Z'' 3.91

(A) 0.02 = (Total Current Assets 2.41b - Total Current Liabilities 2.13b) / Total Assets 16.20b

(B) 0.61 = Retained Earnings (Balance) 9.84b / Total Assets 16.20b

(D) 1.11 = Book Value of Equity 9.80b / Total Liabilities 8.82b

Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.12

1. Piotroski 8.0pt = 3.0

2. FCF Yield 5.29% = 2.64

3. FCF Margin 12.84% = 3.21

4. Debt/Equity 0.88 = 2.13

5. Debt/Ebitda 2.78 = -1.44

6. ROIC - WACC (= 3.03)% = 3.79

7. RoE 13.75% = 1.15

8. Rev. Trend 90.86% = 6.81

9. EPS Trend 76.48% = 3.82

What is the price of DGX shares?

As of October 29, 2025, the stock is trading at USD 178.28 with a total of 1,434,000 shares traded.
Over the past week, the price has changed by -3.44%, over one month by -5.17%, over three months by +6.69% and over the past year by +16.50%.

Is Quest Diagnostics a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Quest Diagnostics (NYSE:DGX) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 75.12 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DGX is around 180.29 USD . This means that DGX is currently overvalued and has a potential downside of 1.13%.

Is DGX a buy, sell or hold?

Quest Diagnostics has received a consensus analysts rating of 3.89. Therefore, it is recommended to buy DGX.

Strong Buy: 8
Buy: 1
Hold: 10
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DGX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	196.6	10.3%
Analysts Target Price	196.6	10.3%
ValueRay Target Price	197.2	10.6%

DGX Fundamental Data Overview October 26, 2025

Market Cap USD = 20.38b (20.38b USD * 1.0 USD.USD)
P/E Trailing = 21.5089
P/E Forward = 17.1233
P/S = 1.8786
P/B = 2.7996
P/EG = 1.4646
Beta = 0.563
Revenue TTM = 10.85b USD
EBIT TTM = 1.58b USD
EBITDA TTM = 2.14b USD
Long Term Debt = 5.62b USD (from longTermDebt, last fiscal year)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.95b USD (from netDebt column, last quarter)
Enterprise Value = 26.33b USD (20.38b + Debt 6.38b - CCE 432.0m)
Interest Coverage Ratio = 5.60 (Ebit TTM 1.58b / Interest Expense TTM 282.0m)
FCF Yield = 5.29% (FCF TTM 1.39b / Enterprise Value 26.33b)
FCF Margin = 12.84% (FCF TTM 1.39b / Revenue TTM 10.85b)
Net Margin = 8.93% (Net Income TTM 969.0m / Revenue TTM 10.85b)
Gross Margin = 33.30% ((Revenue TTM 10.85b - Cost of Revenue TTM 7.24b) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 34.15%)
Tobins Q-Ratio = 1.63 (Enterprise Value 26.33b / Total Assets 16.20b)
Interest Expense / Debt = 1.08% (Interest Expense 69.0m / Debt 6.38b)
Taxrate = 22.92% (77.0m / 336.0m)
NOPAT = 1.22b (EBIT 1.58b * (1 - 22.92%))
Current Ratio = 1.13 (Total Current Assets 2.41b / Total Current Liabilities 2.13b)
Debt / Equity = 0.88 (Debt 6.38b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 2.78 (Net Debt 5.95b / EBITDA 2.14b)
Debt / FCF = 4.27 (Net Debt 5.95b / FCF TTM 1.39b)
Total Stockholder Equity = 7.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.98% (Net Income 969.0m / Total Assets 16.20b)
RoE = 13.75% (Net Income TTM 969.0m / Total Stockholder Equity 7.05b)
RoCE = 12.46% (EBIT 1.58b / Capital Employed (Equity 7.05b + L.T.Debt 5.62b))
RoIC = 9.39% (NOPAT 1.22b / Invested Capital 12.95b)
WACC = 6.36% (E(20.38b)/V(26.76b) * Re(8.09%) + D(6.38b)/V(26.76b) * Rd(1.08%) * (1-Tc(0.23)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.50% ; FCFE base≈1.25b ; Y1≈1.28b ; Y5≈1.42b
Fair Price DCF = 223.6 (DCF Value 24.87b / Shares Outstanding 111.2m; 5y FCF grow 2.43% → 3.0% )
EPS Correlation: 76.48 | EPS CAGR: 10.41% | SUE: 1.93 | # QB: 4
Revenue Correlation: 90.86 | Revenue CAGR: 7.08% | SUE: 3.44 | # QB: 2

Additional Sources for DGX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle